IMMUNITYBIO, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
IMMUNITYBIO, INC. (IBRX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$4.07 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2021-03-04
- IMMUNITYBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $1.44M, a 78.31% decline year-over-year.
- IMMUNITYBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was $6.66M.
- IMMUNITYBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was -$12.68M, a 329.93% decline year-over-year.
- IMMUNITYBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-03-31 was $5.51M.
- IMMUNITYBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$4.07M.
- IMMUNITYBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was -$1.31M.
- IMMUNITYBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was -$7.05M, a 144.66% decline from fiscal 2017.
- IMMUNITYBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was $15.79M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$4.07M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $12.18M 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $87.19M 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $1.44M 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | -$1.31M 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $1.47M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $708.00K 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $6.66M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$7.05M 10-K · filed 2021-03-04 | |||
| 2018-09-30 | -$8.56M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | -$7.75M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | -$12.68M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $15.79M 10-K · filed 2020-03-25 | |||
| 2017-09-30 | $12.84M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $30.96M 10-Q · filed 2018-08-06 | |||
| 2017-03-31 | $5.51M 10-Q · filed 2018-05-07 | |||
| 2016-12-31 | -$167.82M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |